Development
Recursion Pharmaceuticals, Inc.
RXRX
$5.49
$0.9220.13%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -36.99% | -18.49% | -11.15% | -17.51% | -28.42% |
| Total Depreciation and Amortization | 107.57% | 86.15% | 51.33% | 30.16% | 39.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 68.40% | 54.83% | 65.41% | 81.45% | 98.70% |
| Change in Net Operating Assets | -147.90% | -138.98% | -136.78% | -133.27% | 34,387.91% |
| Cash from Operations | -244.55% | -158.62% | -206.05% | -364.08% | 47.34% |
| Capital Expenditure | 67.74% | 46.74% | 27.44% | -53.26% | 6.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.05% | -99.87% | 197.13% | 197.86% | 199.29% |
| Cash from Investing | -105.29% | -110.55% | 138.43% | 140.91% | 171.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -751.11% | -7.95% | 99.27% | 99.28% | 99.30% |
| Issuance of Common Stock | -8.76% | 1,784.85% | 1,415.32% | -67.27% | -67.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -9.21% | 1,799.22% | 6,197.45% | -66.37% | -66.34% |
| Foreign Exchange rate Adjustments | 161.24% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -159.78% | -212.93% | 73.56% | -111.96% | 835.93% |